Picard Medical, Inc. IPO - What You Need to Know

Thinking about the Picard Medical IPO? Before you invest, let’s break down what this company does in plain English. Here is a friendly guide to help you decide if this fits your portfolio.

1. What does this company do?

Picard Medical owns SynCardia Systems, LLC. They make the SynCardia Temporary Total Artificial Heart (TAH). It is the only FDA-approved device in the U.S. that replaces both failing heart ventricles. It acts as a "bridge to transplant," keeping patients alive while they wait for a donor heart. The company makes money by selling these artificial hearts, portable "Freedom" drivers, and surgical tools. They have a proven track record, with over 2,100 implants across 27 countries.

2. What is their big goal?

They plan to use the money from this IPO for three main projects:

• The "Unicorn" Driver: A more portable pump to help patients move around easily. They expect to start clinical testing in late 2026.
• The "Emperor" TAH: Their "holy grail" project. This is a fully internal heart that removes the need for external tubes. They plan to start animal trials in late 2025.
• Global Expansion: They want to grow sales abroad, including a potential joint venture in China to handle local manufacturing and regulations.

3. The Financial Reality: A Tough Road

This is important: the company is losing money. In 2024, they lost about $21 million. In the first three months of 2025, they lost another $5.6 million. Management admits there is "substantial doubt" they can stay in business. They may run out of money within 12 months without raising more. As of March 31, 2025, they had less than $700,000 in cash—a very tight spot for a company with high research and operating costs.

4. The "Controlled Company" Factor

After the IPO, a venture capital firm called Hunniwell will control about 54.8% of the voting power. Because they own over half the stock, Picard Medical is a "controlled company." This means they can skip certain rules, like having a board made up entirely of independent members. As a result, you will have little say in board decisions or major company changes.

5. What are the main risks?

• Manufacturing Bottlenecks: These hearts require manual assembly by specialized technicians. This makes it hard to scale up production quickly.
• Supply Chain Fragility: They rely on single suppliers for key parts. If a supplier has issues, the company has no backup. Finding a new supplier would require a long, expensive FDA approval process.
• Legal & Regulatory: They are working to regain their CE Mark to sell in Europe. Also, as patents expire, they must rely on trade secrets to stay ahead of competitors.
• Dilution: Insiders hold many stock options. If they use these, the company will issue more shares, which reduces your ownership percentage and your share of future profits.

6. The IPO Details

• Ticker Symbol: PMI | Exchange: NYSE American
• Price: $4.00 per share
• Total Shares: 4.25 million shares

7. Should you buy?

You are betting on a company that is burning cash and needs this IPO to survive. While they have a unique, life-saving product, they face major hurdles. They must fix their manufacturing, regain international licenses, and successfully develop new technology. This is a high-risk investment where the company’s survival depends on its ability to execute its plans and raise more money later.

Investor Tip: Before buying, ask yourself if you are comfortable with the "all or nothing" nature of this investment. Because the company is in such a tight cash position, this stock is likely to be very volatile. If you decide to proceed, consider it a speculative portion of your portfolio rather than a core holding.

Disclaimer: I am an AI, not a financial advisor. IPOs are volatile. Never invest money you cannot afford to lose, and read the official 424B4 filing on the SEC website.